A step-by-step reconstruction of how ORION's Impact Chain combines ClinicalTrials.gov trial data with market signal to reason about a real FDA regulatory decision — two days before the outcome.
This article is published after the FDA's decision was already public. It reconstructs the reasoning ORION's Impact Chain would produce two days before that decision, using the real, publicly disclosed target action date and trial data — it does not claim ORION generated this analysis live in real time on that date. The real outcome is included below, in its own section, because it is now public record and citing it accurately is part of showing our work honestly — not because ORION predicted it. This piece demonstrates ORION's analysis process. For ORION's actual, unedited forward-looking accuracy statistics, see the Track Record page, which is computed live and never curated for presentation.
| Company / Drug | Regeneron Pharmaceuticals & Sanofi — Dupixent® (dupilumab) |
| Indication under review | Allergic Fungal Rhinosinusitis (AFRS), ages 6+ with prior sino-nasal surgery |
| Real FDA target action date | February 28, 2026 (priority review sBLA, accepted November 2025) |
| Reconstruction date ("D-2") | February 26, 2026 |
| Real outcome (public record) | Approved — announced February 24, 2026 (ahead of the target action date) |
| Sources | ClinicalTrials.gov (NCT04684524, LIBERTY-AFRS-AIMS), Regeneron/Sanofi investor press releases, FDA public priority-review disclosures |
Dupixent (dupilumab) is an IL-4Rα antagonist already approved for eight other indications. In November 2025, the FDA accepted Regeneron and Sanofi's supplemental Biologics License Application (sBLA) for a ninth indication — Allergic Fungal Rhinosinusitis (AFRS) — for Priority Review, with a target action date of February 28, 2026. AFRS is a chronic type-2 inflammatory sinus disease; no medicine was specifically indicated for it at the time.
The sBLA was supported by the Phase 3 LIBERTY-AFRS-AIMS trial (NCT04684524): 62 patients randomized 1:1 to dupilumab (n=33) or placebo (n=29) for 52 weeks. The trial met its primary and secondary endpoints — a 50% reduction in CT sinus opacification at week 52 versus 10% on placebo, nasal congestion improvement in 81% versus 11% of patients, nasal polyp score reduction of 63% versus 4%, and a 92% reduction in the risk of needing systemic corticosteroids or surgery. This status — Phase 3 complete, primary and secondary endpoints met, Priority Review granted, first-in-indication — is exactly the kind of structured, dated ClinicalTrials.gov record ORION's Clinical Risk and Pipeline Strength components are built to read.
Per docs/ORION_BUY_SCORE_SPEC.md and the Impact Chain methodology (Whitepaper §6), a clinical-trial-status change is one of exactly two upstream signal types with a live path to a real ORION score.
Input event: LIBERTY-AFRS-AIMS reports Phase 3 completion with primary and secondary endpoints met; FDA grants Priority Review with a Feb 28, 2026 target action date.
Affected entity: REGN — Pipeline Strength / Clinical Risk components
A completed, endpoint-meeting, priority-reviewed Phase 3 trial in a first-in-indication setting lowers measured clinical/regulatory risk and raises Pipeline Strength — both structured inputs to Buy Score, not narrative judgment. This is a directly disclosed regulatory and trial-registry fact, so ORION tags it verified_causal, not an inference.
The second live-scored signal type is a price or analyst-target move flowing into Institutional Confidence. On any given date, ORION reads REGN's prevailing price and 3-month momentum from Yahoo Finance and its sell-side analyst price target — a positive-but-not-euphoric setup (spot trading below consensus target, momentum modestly positive heading into a binary regulatory date) is the kind of tile Institutional Confidence is built to register as a proxy for market sentiment, distinct from and cross-checked against the clinical signal in Step 1. We are not asserting a specific historical price figure for Feb 26, 2026 here; doing so without a verified source would be exactly the kind of unverified-presented-as-verified claim this piece is committed to avoiding.
With one verified clinical signal and one illustrative market-signal type in hand, Impact Chain's role is to show — step by step, each with its own evidence and confidence tag — how a catalyst like this is classified. ORION's FDA Calendar schema tags each tracked catalyst with an expected_impact level (medium / high / very_high); a first-in-indication Priority Review approval, backed by a positive, endpoint-meeting Phase 3 result and no existing approved competitor in that specific indication, is the profile that schema classifies at the top of that scale — VERY HIGH IMPACT — reflecting the size of the regulatory and clinical signal, not a probability or forecast of the vote itself.
Clinical signal — Phase 3 met, Priority Review granted → Pipeline Strength / Clinical Risk inputs move
Category placement — first-in-indication + Priority Review + positive pivotal data matches ORION's VERY HIGH IMPACT catalyst profile
Downstream commercial sizing — peak-sales or market-share impact if approved
The last step matters as much as the first two: ORION does not carry this reasoning chain into a revenue or valuation estimate, because it has no live model for that. Per the honesty rule enforced in code (Whitepaper §6), any step past a live scoring destination is always tagged speculative with its quantitative impact forced to null — shown as a labeled hypothesis, never as a computed number.
The FDA approved Dupixent for Allergic Fungal Rhinosinusitis, announced by Regeneron and Sanofi on February 24, 2026 — four days ahead of the February 28 target action date — making it dupilumab's ninth FDA-approved indication and the first medicine specifically indicated for AFRS. This is stated here as a fact of public record, sourced to Regeneron/Sanofi's investor disclosure, not as evidence that ORION "called" it: this entire piece was written and published after that announcement, walking through the reasoning ORION's Impact Chain produces from public data, not a real-time prediction made in advance of it.
If ORION had generated a live prediction for this specific event ahead of time, it would appear — permanently, unedited, whether right or wrong — in ORION's public Track Record alongside every other prediction ORION has made.